Business Development

Aquired exclusive distribution righs for Natesto, is the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism. Natesto has launched in Taiwan.

Obtained the exclusive rights of ASC-J9 acne cream in Taiwan, Korea, Australia, New Zealand, and Southeast Asia from AndroScience. The phase II clinical trial is completed and promising, the development project plan to move forward

Cooperated with French company Besins for long periods, obtaining exclusive rights to sell the company’s hormone products in Taiwan’s market

Signed a cooperative agreement with American company TissueTech in 2016, officially acquiring exclusive rights for the company’s next series of opthalmologic tissue products in Asia Pacific. Aminograft has received marketing authorization in Taiwan

Supply Agreement was signed with US company Carlsbad Technology for muscle relaxant Carisoprodol tablet selling in US.

Signed agreement with Italian Chiesi Pharmaceutical Company for exclusive rights of Foster® and Trimbow® in Taiwan, Malaysia, Singapore and Philippines. Foster® was approved in Taiwan and covered by National Healthcare Insurance since 2010 and also approved in above countries since 2011. In 2022, obtained exclusive rights of 3 rare dieseses drugs in Taiwan, Hong Kong and Southest Asia markets.

Authorized by Switzerland company Debiopharm to sell its cancer drugs in Taiwan and Southeast Asia

Signed agreement wihth HRA pharma, obtained the exclusive rights of Ella®/Esmya, new mechanism drug to treat uterine fibroids, which has approved by TFDA

Distributed the Company’s new drugs in the Taiwan market.

Cooperated with French company Pierre Fabre for long periods, obtaining exclusive rights to sell the company’s anti-cancer products in Taiwan and Southeast Asia

Signed a cooperation agreement with Plethora Solutions Limited in 2018, officially acquiring exclusive distribution rights for Fortacin, premature ejaculation treatment, in Taiwan and Southeast Asia. Fortacin has launched in Taiwan and Hong Kong.

Obtained permit since 2001 for exclusive rights for the antihypertensive drug Zanidip of an Italian pharmaceutical company Recordati in Taiwan’s market

Aquired Taiwan and Hong Kong disctribution rights of the latest long-actiong injection for the treatment of schizophrenia.

Exclusively distributed the Company’s niche generic drug for the treatment of blood tumor in Taiwan and Philippine markets

Entered cooperative agreement with Second Sight in 2016, acquiring exclusive distribution rights for the Argus II Retinal Prosthesis System in Taiwan and obtained permission to sell in Taiwan

Granted an exclusive right to distribute and commercialize ZYNLONTA® in Taiwan and Singapaore , the first and only CD19-targeted ADC.